logo
Katana's $240 Million Launch Bets On The Future Of Verticalized DeFi

Katana's $240 Million Launch Bets On The Future Of Verticalized DeFi

Forbes30-06-2025
Vintage illustration of a congregation worshipping 'The Almighty Dollar' in a crowded cathedral; ... More lithograph, 1907. (Photo)
Katana just launched its mainnet with over $240 million in what the team calls 'productive TVL,' meaning capital that is actively deployed into lending and trading strategies rather than sitting idle. But Katana is not trying to be another general purpose blockchain. Incubated by Polygon Labs and GSR, it is a vertically integrated DeFi chain built to concentrate liquidity, generate real yield, and route value back to users. It offers a capital-efficient alternative to the fragmented sprawl of today's Layer 2 ecosystems.
Rather than supporting a wide range of applications with competing incentives, Katana takes an opinionated approach. It launches with a curated stack of core protocols: Morpho for lending, Sushi for trading, and Vertex for perps. Each is designed to work in concert. Bridged assets are immediately deployed into yield-generating strategies on Ethereum through a system called VaultBridge. Sequencer fees are recycled into liquidity pools. Stablecoin yields from off-chain assets are routed back into the ecosystem. Every piece is built to amplify the same goal: deeper liquidity and sustainable yield.
The result is a blockchain that functions more like a coordinated financial venue than an open playground. By concentrating activity around a few high-performing protocols and aligning incentives at the chain level, Katana avoids the liquidity fragmentation that has plagued DeFi for years. Instead of competing apps splitting users and capital, Katana funnels value through a shared infrastructure designed to maximize output per dollar.
That approach is already showing traction. Ahead of launch, Katana attracted hundreds of millions in assets that are not just bridged, but actively earning yield. The team emphasizes that this reflects real economic activity, not deposits chasing short-term incentives. It is a signal that users are putting capital to work, not just parking it.
Katana is also positioning itself to solve the structural liquidity challenges that have long limited institutional participation in DeFi. 'Institutions want to participate directly in crypto onchain, but the current state of fragmented liquidity across chains and platforms makes it nearly impossible for them to operate at the scale they require,' said Marc Boiron, CEO of Polygon Labs and co-contributor to Katana. 'By concentrating liquidity across chains and protocols into fewer, more accessible pools, we can support high-volume, capital-efficient transactions. This is essential not just for enabling institutional involvement, but for unlocking the next phase of growth in decentralized finance.'
Institutional appeal is also central to Katana's strategy. With backing from GSR and infrastructure built to meet compliance and performance expectations, the chain is positioning itself as a credible venue for serious capital. Features like real-time rewards, transparent APY breakdowns, and sequencer fee recycling are designed to meet the demands of firms that need more than narratives, but rather need yield, efficiency, and accountability.
At the core of this system is VaultBridge, a mechanism that deploys bridged assets like ETH, USDC, and wBTC into yield-generating strategies on Ethereum. Instead of waiting for DeFi activity to happen on Katana itself, the chain immediately puts capital to work on established protocols like Morpho, then routes the earned yield back to users. This allows Katana to offer competitive returns from day one, without relying solely on token emissions to attract liquidity.
Alongside VaultBridge, Katana introduces chain-owned liquidity, a system that redirects sequencer fees back into the network. Rather than distributing fees to validators or external stakeholders, Katana uses them to deepen liquidity in its core protocols. This creates a self-reinforcing loop: as activity on the chain increases, so does the pool of capital available to users, which in turn improves trading execution, reduces slippage, and boosts overall yield.
Katana also integrates AUSD, a stablecoin issued by Agora that captures off-chain yield from U.S. Treasuries and repo markets. That yield is then recycled into Katana's DeFi ecosystem, further enhancing returns for users. By layering multiple revenue streams such as on-chain lending, sequencer fees, and real-world asset yield, Katana aims to offer sustainable, baseline yield that does not depend on aggressive incentives or speculative activity.
This design reflects a broader shift in how DeFi infrastructure is being built. Rather than chasing composability across countless apps, Katana prioritizes integration and coordination. Its curated set of protocols is meant to work together, not compete. That approach may limit surface-level diversity, but it significantly increases capital efficiency and user experience. By focusing on liquidity depth and aligned incentives, Katana is aiming to build a DeFi environment that is optimized from the base layer up.
It is also what sets Katana apart from other vertical DeFi experiments like Blast and Berachain. Where Blast focused on rebasing assets and Berachain introduced a tri-token governance model, Katana's approach is centered on turning every layer of infrastructure into a yield engine. As Jin explored in his article 'Katana: The Biggest Bet in DeFi?', this is perhaps the clearest articulation of DeFi verticalization to date. Bridged assets earn yield before they even reach the chain. Sequencer fees fund liquidity. Governance bribes and emissions are directed through a vote-locked token model. The result is a system where capital does not just sit; it compounds.
That compounding is tied directly to Katana's native token, KAT. Users who lock KAT into its vote-escrowed form, vKAT, gain the ability to direct emissions, earn a share of protocol fees, and receive incentives from protocols competing for liquidity. The more activity on the chain, the more value flows to vKAT holders.
The token design reflects Katana's broader thesis: that the chain itself should function as a yield aggregator. Instead of relying on hype or narrative to support its token, Katana aims to tie KAT directly to the economic output of the ecosystem. As more protocols launch, more users participate, and more assets are deployed, the value generated flows back to those who are actively securing and governing the network.
That alignment between users, protocols, and the chain itself is part of what makes Katana's model appealing to institutions. According to GSR President Jakob Palmstierna, firms are no longer interested in speculative experiments. 'Fortune 500 firms demand the strongest proof of value possible,' he said. 'The true measure of blockchain utility isn't the number of financial dApps, but whether the infrastructure delivers economic value at scale.' By combining transparent yield sources, sustainable incentives, and a clear link between usage and revenue, Katana is aiming to meet that standard.
According to a recent report by Blockworks, Katana is built using Polygon's CDK framework and the OP Stack, with finality provided by Succinct's SP1 zk prover. This technical foundation allows the chain to offer one-second block times, high throughput, and fast bridging between Ethereum and other AggLayer-connected chains. AggLayer is Polygon's new interoperability layer for connecting rollups, offering a unified user experience across chains. With a clear path toward meeting L2Beat's Stage 1 decentralization benchmarks, Katana is positioning itself as both performant and credibly neutral, two key requirements for larger players entering the space.
Still, Katana's success will depend on more than infrastructure. Like any new chain, it faces the challenge of attracting sticky liquidity and sustained user activity. While early incentives and partner integrations have helped drive momentum, the long-term test will be whether the ecosystem can continue delivering competitive yields without overrelying on emissions. If the real yield strategy works as intended, Katana could offer a blueprint for how chains generate value, not just through usage but through coordinated economic output.
Katana is not promising to reinvent DeFi from scratch. It is offering something more pragmatic and, potentially, more powerful: a chain that treats yield, liquidity, and alignment as first principles. By concentrating value creation instead of scattering it, Katana is betting that the future of onchain finance will reward depth over breadth. It is not trying to be a general purpose blockchain. It is trying to be a financial institution built on crypto rails.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

Yahoo

time7 minutes ago

  • Yahoo

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio

US securities regulator announces AI task force
US securities regulator announces AI task force

Yahoo

time7 minutes ago

  • Yahoo

US securities regulator announces AI task force

(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Yahoo

time7 minutes ago

  • Yahoo

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store